Varubi

Indicated For

Chemotherapy-induced nausea and vomiting (CINV), delayed phase

About This Medication

# TerSera SupportSource Patient Assistance Program - Varubi Patient Guide: How to Get Varubi at Low or No Cost Varubi (rolapitant) is an prescription medication used to prevent delayed nausea and vomiting caused by chemotherapy. The **TerSera SupportSource Patient Assistance Program** helps **uninsured or underinsured patients** who can't afford Varubi get it **free of charge** if they qualify based on income and other criteria.[3][6] ## About Varubi (Rolapitant) **Varubi** is an oral tablet taken before chemotherapy to block NK1 receptors in the brain, reducing **delayed nausea and vomiting**—a common side effect that can start 24 hours or more after treatment. It's often used with other anti-nausea drugs like dexamethasone and a 5-HT3 receptor antagonist (e.g., ondansetron). Approved by the FDA for adults receiving certain chemotherapy regimens like cisplatin, it's especially helpful for patients undergoing cancer treatment who struggle with post-chemo sickness affecting eating, hydration, and recovery.[3] Common side effects include fatigue, diarrhea, headache, and loss of appetite. Always take as prescribed—usually a single 90 mg dose 1-2 hours before chemo. **Talk to your doctor** about Varubi if nausea disrupts your life during treatment. This program makes it accessible when costs are a barrier.[4] ## Who Qualifies for the Program? The TerSera SupportSource Patient Assistance Program targets patients facing financial hardship. Key eligibility: - **Residency**: Must be a permanent, legal U.S. resident.[6] - **Prescription**: Valid prescription for Varubi for an FDA-approved use.[3][6] - **Insurance**: Uninsured or underinsured (insurance doesn't cover Varubi or out-of-pocket costs are unaffordable). Medicare Part D patients may qualify if they meet income rules—program helps navigate this.[2][6] - **Income**: Based on **annual gross household income**. Specific dollar thresholds aren't publicly listed and vary; eligibility confirmed during application. Patients certify income accuracy and allow consumer report checks.[3] This program provides **free medication for up to 1 year** to approved patients, shipped directly to your home.[7] ## Income Eligibility Breakdown Exact income limits aren't detailed in public sources, as they're assessed case-by-case based on **annual gross household income** and federal poverty level (FPL) considerations. Contact TerSera SupportSource for your situation. Here's a general guide based on similar TerSera programs: | Household Size | Estimated Max Income (e.g., ~400-500% FPL)* | Notes | |---------------|---------------------------------------------|-------| | 1 (Individual) | Not specified; call to verify | Gross household income required[3] | | 2 (Couple) | Not specified; call to verify | Includes all household earners | | 3 | Not specified; call to verify | Proof like tax returns needed | | 4+ | Not specified; call to verify | Adjusted per family size | *Estimates only—**actual thresholds set by TerSera**. FPL changes yearly (e.g., 2026 guidelines). Provide recent pay stubs, tax returns, or W-2s. If income changes, notify program immediately.[3][6] ## Insurance Requirements - **Uninsured**: Fully eligible if other criteria met.[6] - **Underinsured**: Qualify if copays/deductibles make Varubi unaffordable.[2] - **Medicare/Medicaid**: Possible via specialty pharmacy triage to assistance; not automatic exclusion.[2][6] - **Commercial Insurance**: Program may refer to **co-pay assistance** (as low as $0 copay, up to $10,000/year) instead of free drug.[2][4] TerSera SupportSource verifies benefits, handles prior authorizations, and appeals. Submit insurance cards (front/back).[5] ## Step-by-Step Application Process 1. **Get Prescribed**: Ask your doctor for Varubi. They complete the **TerSera SupportSource Enrollment Form** (download from terserasupportsource.com or call).[3][4] 2. **Gather Documents**: - Completed enrollment form (both sides, signed by you and doctor).[3] - **Proof of income** (e.g., last 2 pay stubs, tax return, W-2).[3] - **Prescription** for Varubi.[3] - Insurance cards (or note no insurance).[5] 3. **Submit by Fax**: Doctor's office faxes to **1-855-836-3066**. No online portal; fax only.[3] 4. **Phone Support**: Call **1-855-686-8725** (M-F, 9AM-6PM ET) for help, status, or questions. Pharmacists available 24/7 via specialty pharmacy.[2] 5. **Approval Notification**: Program reviews; you'll be contacted if more info needed.[2] **Patient Tip**: Start with your doctor's office—they handle most paperwork. Sign authorizing info sharing for eligibility check.[3] ## Timeline and Delivery - **Processing**: Varies; specialty pharmacy verifies form, benefits, then approves. Expect **2-4 weeks** typically for PAPs, but call for updates.[2] - **Delivery**: If approved, **shipped free to your home** (or doctor's office in some cases). Up to 1-year supply.[7] - **Refills**: **Reauthorization required**—resubmit form/proof periodically as income/coverage changes.[3] Track via phone; notify of address changes. ## Alternatives if Denied - **Appeal**: Ask reason (e.g., income too high) and resubmit updated docs.[2] - **Co-Pay Program**: For insured patients, $0 copay up to $10,000/year.[2][4] - **Other Foundations**: TerSera refers to copay assistance foundations.[5] - **RxAssist.org**: Search more PAPs.[10] - **State Programs**: Check Medicaid extra help or cancer-specific aid. - **Generic Alternatives**: No biosimilars; discuss other antiemetics with doctor (e.g., aprepitant). **Call TerSera**—they triage to best option.[4] ## Important Disclaimer This guide summarizes publicly available info as of latest sources. **Eligibility, terms change**—contact **TerSera SupportSource at 1-855-686-8725** or visit terserasupportsource.com for official details. Not medical/financial advice. Consult doctor/pharmacist. Program may end or modify without notice. Income verification strict; falsification disqualifies. HIPAA protections apply.[3][6] (Word count: 1028)

Program information last verified: March 30, 2026